Latest Period
Q1 2026
Security Snapshot
CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX) Institutional Ownership
CUSIP: 230770109
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
28
Shares (Excl. Options)
2,761,293
Price
$3.25
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common stock
- Symbol
- CPIX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,761,293
- Total 13F value
- $8,972,896
- Portfolio coverage rank
- 0%
- Share change
- -191,797
- Value change
- -$699,823
- Number of holders
- 28
- Shares outstanding
- 15,075,924
- SEC-reported price per share
- $4.85
- Insider filing price
- $4.85
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CPIX - CUMBERLAND PHARMACEUTICALS INC - Common stock is tracked under CUSIP 230770109.
- 28 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 27 to 28 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $11,770,877 to $8,972,896.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 28 institutions filings for Q1 2026.
Security key
230770109
Latest holder period
Q1 2026
13F holders
28
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
CPIX full holder history
CUMBERLAND PHARMACEUTICALS INC SEC filings
CUMBERLAND PHARMACEUTICALS INC company facts
CUMBERLAND PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 230770109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
CPIX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| KAZIMI A J | 38% | -5.9% | $27,324,812 | +$409,974 | 5,789,155 | +1.5% | A.J. Kazimi | 30 Jan 2026 |
| Ikarian Capital, LLC | 4.9% | $3,545,020 | 730,932 | Ikarian Capital, LLC | 31 Mar 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 4% | -30% | $1,618,467 | -$571,171 | 598,634 | -26% | Integrated Core Strategies (US) LLC | 30 Sep 2025 |
As of 31 Mar 2026, 28 institutional investors reported holding 2,761,293 shares of CUMBERLAND PHARMACEUTICALS INC - Common stock (CPIX). This represents 18% of the company’s total 15,075,924 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
18%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 3.7% | 553,153 | -0.5% | 0.26% | $1,797,748 |
| RENAISSANCE TECHNOLOGIES LLC | 3.1% | 470,696 | -0.31% | 0% | $1,529,762 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.4% | 361,759 | 0% | 0% | $1,175,717 |
| DIMENSIONAL FUND ADVISORS LP | 1.8% | 276,359 | +1.5% | 0% | $898,167 |
| PERCEPTIVE ADVISORS LLC | 1.3% | 196,978 | -42% | 0.01% | $640,179 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 1.1% | 163,468 | 0% | 0.01% | $531,271 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.85% | 127,694 | -0.63% | 0.01% | $415,006 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.76% | 114,293 | +6.5% | 0% | $371,499 |
| J. Goldman & Co LP | 0.54% | 81,040 | -14% | 0.01% | $263,380 |
| Bank of New York Mellon Corp | 0.39% | 58,458 | -19% | 0% | $189,988 |
| BlackRock, Inc. | 0.38% | 56,891 | +8.2% | 0% | $184,896 |
| VANGUARD FIDUCIARY TRUST CO | 0.3% | 45,623 | 0% | 0% | $148,275 |
| ACADIAN ASSET MANAGEMENT LLC | 0.29% | 44,288 | 0% | 0% | $143,000 |
| STATE STREET CORP | 0.26% | 39,510 | +17% | 0% | $128,408 |
| Marex Group plc | 0.24% | 36,423 | 0% | $118,375 | |
| XTX Topco Ltd | 0.16% | 24,006 | 0% | $78,020 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.13% | 20,252 | 0% | $65,819 | |
| NORTHERN TRUST CORP | 0.13% | 19,603 | 0% | 0% | $63,710 |
| Cresset Asset Management, LLC | 0.13% | 19,475 | +11% | 0% | $63,294 |
| CITADEL ADVISORS LLC | 0.11% | 16,643 | -24% | 0% | $54,090 |
| JANE STREET GROUP, LLC | 0.1% | 14,607 | 0% | $47,473 | |
| TWO SIGMA INVESTMENTS, LP | 0.07% | 11,085 | -55% | 0% | $36,026 |
| UBS Group AG | 0.03% | 5,189 | -66% | 0% | $16,864 |
| MORGAN STANLEY | 0.02% | 3,260 | 0% | 0% | $10,595 |
| Capital Advisors, Ltd. LLC | 0% | 437 | 0% | 0% | $1,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,761,293 | $8,972,896 | -$699,823 | $3.25 | 28 |
| 2025 Q4 | 2,957,494 | $11,770,877 | -$1,253,172 | $3.98 | 27 |
| 2025 Q3 | 3,406,057 | $10,626,381 | -$866,501 | $3.12 | 30 |
| 2025 Q2 | 3,682,268 | $12,334,180 | -$2,453,600 | $3.35 | 30 |
| 2025 Q1 | 4,280,014 | $18,146,545 | +$10,361,899 | $4.23 | 33 |
| 2024 Q4 | 1,842,038 | $4,363,682 | -$463,905 | $2.37 | 20 |
| 2024 Q3 | 2,043,812 | $2,614,244 | -$42,881 | $1.28 | 22 |
| 2024 Q2 | 2,077,457 | $3,176,639 | -$134,139 | $1.53 | 22 |
| 2024 Q1 | 2,162,869 | $3,632,852 | -$59,437 | $1.68 | 22 |
| 2023 Q4 | 2,197,513 | $3,885,597 | -$17,577 | $1.79 | 23 |
| 2023 Q3 | 2,207,792 | $4,170,727 | -$310,716 | $1.89 | 20 |
| 2023 Q2 | 2,399,098 | $3,524,781 | -$75,730 | $1.47 | 21 |
| 2023 Q1 | 2,447,258 | $4,771,188 | -$92,987 | $1.95 | 21 |
| 2022 Q4 | 2,493,007 | $5,607,314 | +$78,520 | $2.25 | 22 |
| 2022 Q3 | 2,446,157 | $5,893,000 | -$555,959 | $2.41 | 15 |
| 2022 Q2 | 2,708,341 | $5,621,000 | -$446,941 | $2.08 | 20 |
| 2022 Q1 | 2,897,889 | $8,171,000 | -$99,570 | $2.82 | 24 |
| 2021 Q4 | 2,835,251 | $13,232,000 | +$375,969 | $4.67 | 23 |
| 2021 Q3 | 2,767,210 | $7,429,000 | -$468,259 | $2.68 | 20 |
| 2021 Q2 | 2,937,884 | $8,359,000 | -$812,822 | $2.84 | 24 |
| 2021 Q1 | 3,224,768 | $9,769,000 | -$1,950,699 | $3.03 | 27 |
| 2020 Q4 | 3,875,161 | $11,421,000 | -$521,913 | $2.95 | 24 |
| 2020 Q3 | 4,029,264 | $12,934,000 | -$360,904 | $3.21 | 22 |
| 2020 Q2 | 4,141,182 | $13,791,000 | -$1,829,588 | $3.33 | 23 |
| 2020 Q1 | 4,674,157 | $16,964,000 | +$754,442 | $3.63 | 21 |